Evidence map›Paper›PMID 33902185›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[Liver cirrhosis and secondary osteoporosis].

L Yang, C Q Yang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. [Animal Modeling of Osteoporosis Combined With Liver Cirrhosis and Preliminary Investigation of the Comorbidity Mechanisms].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

L YangDivision of Gastroenterology and Hepatology, Digestive Disease Institute, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
C Q YangDivision of Gastroenterology and Hepatology, Digestive Disease Institute, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
Tongji Hospital · CN

Funding

Clinical Research Plan of SHDC SHDC2020CR2030BNational Natural Science Foundation of China 81670571, 81820108006Shanghai Clinical Key Specialty Project SHSLCZDZK 06801
6 · The paper itself

Abstract

Osteoporosis is a bone loss disease caused by the imbalance of osteoblast and osteoclast. It is a common complication of patients with liver cirrhosis, cholestatic liver disease, and liver transplantation. Over the past few decades, many researchs have raised the awareness of immune cell activation, chronic inflammation, intestinal microflora, etc. in liver cirrhosis and secondary osteoporosis. This article reviews the progress of the epidemiology, pathogenesis, diagnosis and treatment of liver cirrhosis and secondary osteoporosis.

Indexed as

Bone Diseases, MetabolicCholestasisLiver TransplantationOsteoporosisHumansLiver CirrhosisBone mineral densityChronic inflammationGut microbiotaLiver cirrhosisSecondary osteoporosis

Identifiers

PMID33902185
PMCPMC12814200
OpenAlexW3159478400

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.